2021
COVID-19 Impact on Healthcare and Supportive Services for People Who Use Drugs (PWUDs) in Malaysia
Vicknasingam B, Salleh N, Chooi WT, Singh D, Zaharim N, Kamarulzaman A, Chawarski MC. COVID-19 Impact on Healthcare and Supportive Services for People Who Use Drugs (PWUDs) in Malaysia. Frontiers In Psychiatry 2021, 12: 630730. PMID: 33854449, PMCID: PMC8039131, DOI: 10.3389/fpsyt.2021.630730.Peer-Reviewed Original ResearchMethadone maintenance treatment programTake-home dosesMaintenance treatment programCOVID-19 infectionDelivery of medicationsSupportive servicesHIV clinicMMT patientsTreatment disruptionPerson visitsTreatment protocolPatient's homeStudy participantsTreatment programCOVID-19 epidemicPatient flowTelemedicine resourcesCOVID-19 responseMedical personnelMedicationsPatientsLower ratesSemi-structured formatMovement Control OrderRecipients
2014
Profiles of psychiatric symptoms among amphetamine type stimulant and ketamine using inpatients in Wuhan, China
Zhang Y, Xu Z, Zhang S, Desrosiers A, Schottenfeld RS, Chawarski MC. Profiles of psychiatric symptoms among amphetamine type stimulant and ketamine using inpatients in Wuhan, China. Journal Of Psychiatric Research 2014, 53: 99-102. PMID: 24613031, PMCID: PMC4004368, DOI: 10.1016/j.jpsychires.2014.02.010.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScalePsychiatric symptomsAmphetamine-type stimulantsKetamine groupKetamine useAnxiety depressionInpatient psychiatry wardUrine toxicology screenProportion of participantsPsychiatric Rating ScaleLower scoresWard admissionToxicology screenClinical recordsPsychiatry wardInpatient treatmentHigher scoresPrimary drugATS useBPRS subscalesMajor drug problemStudy participantsKetamineSymptomsATS users
2007
Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence
Chawarski MC, Fiellin DA, O'Connor PG, Bernard M, Schottenfeld RS. Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence. Journal Of Substance Use And Addiction Treatment 2007, 33: 411-415. PMID: 17512157, PMCID: PMC3632440, DOI: 10.1016/j.jsat.2007.03.004.Peer-Reviewed Original ResearchConceptsOutpatient clinical settingPatch testingDrug useClinical settingSweat testingEfficacy of buprenorphinePrimary care settingRandomized clinical trialsSelf-reported drug usePositive urine resultsSweat test resultsDrug use monitoringUrine toxicologyOpioid dependenceOutpatient treatmentUrine testingClinical trialsCare settingsOpiate useOpiate dependenceUrine resultsStudy participantsLevel of agreementToxicology testsLow acceptability
2005
Buprenorphine tablet versus liquid: A clinical trial comparing plasma levels, efficacy, and symptoms
Chawarski MC, Moody DE, Pakes J, O'Connor PG, Schottenfeld RS. Buprenorphine tablet versus liquid: A clinical trial comparing plasma levels, efficacy, and symptoms. Journal Of Substance Use And Addiction Treatment 2005, 29: 307-312. PMID: 16311183, DOI: 10.1016/j.jsat.2005.08.011.Peer-Reviewed Original ResearchConceptsTrough concentrationsPlasma concentrationsOpiate-dependent volunteersIllicit opioid usePeak plasma concentrationBuprenorphine doseBuprenorphine tabletsOpioid useWithdrawal symptomsBuprenorphine levelsPlasma levelsTablet doseClinical trialsLarge intersubjectLiquid formulationStudy participantsIntrasubject variabilityPlasma samplesPeak concentrationTablet formulationLiquid dosesDays of maintenanceSymptomsDoseConcentration curve